Biocon (a Biotechnology Company with headquarters in Bangalore, India) has received the marketing authorization from the Drugs Controller general of India for Novel Biologic Itolizumab (used for the treatment of chronic plaque Psoriasis). Itolizumab has an excellent safety profile as indicated during the 52-week clinical study conducted in India. This...